

Oxlumo[™] (lumasiran) – Expanded indication

- On October 6, 2022, <u>Alnylam Pharmaceuticals announced</u> the FDA approval of <u>Oxlumo</u>
 (<u>lumasiran</u>), for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma
 oxalate levels in pediatric and adult patients.
 - Oxlumo was previously approved for this indication to lower urinary oxalate levels only.
- The approval of Oxlumo for the expanded indication was based on ILLUMINATE-C, a single-arm study in 21 patients with PH1, including patients on hemodialysis. Cohort A included 6 patients who did not require dialysis at the time of study enrollment. Cohort B included 15 patients who were on a stable regimen of hemodialysis. The primary endpoint was the percent change in plasma oxalate from baseline to month 6 for Cohort A and the percent change in pre-dialysis plasma oxalate from baseline to month 6 for Cohort B.
 - The percent change from baseline to month 6 in plasma oxalate levels in Cohort A was a least-squares (LS) mean difference of -33% (95% CI: -82, 15) and in Cohort B it was -42% (95% CI: -51, -34).
- The recommended dosing regimen of Oxlumo consists of loading doses (monthly for 3 doses) followed by maintenance doses (beginning 1 month after the last loading dose) administered subcutaneously. Dosing is based on actual body weight.
 - Refer to the Oxlumo drug label for complete dosing information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.